Skeletal muscle metabolism in patients with malignant tumor.
about
Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic ratsActivation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF)Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes.Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice.NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle.Molecular pathways leading to cancer cachexia.Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself.Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli.Induction of muscle protein degradation by a tumour factorPathophysiology of cancer cachexia.Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.Cancer cachexia update in head and neck cancer: Pathophysiology and treatment.The role of cytokines in muscle wasting: its relation with cancer cachexia.Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failureIncreased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexiaAmino acid metabolism and inflammatory burden in ovarian cancer patients undergoing intense oncological therapy.The origins of cachexia in acute and chronic inflammatory diseases.Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acidInterleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.Increased mRNA levels for components of the lysosomal, Ca2+-activated, and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients.Metabolic effects of cancer.Role of protein kinase C and NF-kappaB in proteolysis-inducing factor-induced proteasome expression in C(2)C(12) myotubes.Direct biochemical analysis of human muscle tissue in hospital malnutrition.Aspects of amino acid and protein metabolism in cancer-bearing states.Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions.Glucose tolerance in relation to skeletal muscle enzyme activities in cancer patients.Metabolic alteration in patients with cancer: nutritional implications.Pharmacological interference with tissue hypercatabolism in tumour-bearing ratsDevelopment of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factorThe oxidation of leucine in tumour-bearing rats.Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia.Amino acid metabolism in tumour-bearing mice.Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects.Metabolic Changes During Cancer Cachexia Pathogenesis.Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells.Withania somnifera modulates cancer cachexia associated inflammatory cytokines and cell death in leukaemic THP-1 cells and peripheral blood mononuclear cells (PBMC's).
P2860
Q28344272-D51886B8-C839-48D6-A3DA-230C60A59A33Q28344353-7B57DBC2-B92D-4F50-839B-97871939C2FAQ33316844-D7080595-132A-44FD-9FD0-2E5D2E52FA52Q33349016-88F435C4-2868-4D28-9BA1-B3A65F7CC1CCQ33979314-1A6EF42C-7DC8-4AAD-A321-F72FA3F5C7C0Q33985083-1A39CEDE-B834-49A9-A8C6-47A772B8EBF6Q33990203-3595200D-C267-4525-A471-272CB47BDD03Q33991186-A5F0D0EA-A0A2-4AF3-B044-946392BBB44BQ34004957-F7535FB8-F01F-48DD-8243-F345AD732B6AQ34065542-57CA2263-A7FC-40DA-8971-FC00955C3D95Q34139514-81736193-A195-4D0A-BFAA-9A6F34D305FDQ34315320-1581AD5A-8C71-4429-88E2-4DDEB0E146B6Q35122201-34875850-80C4-498E-B505-90419EAD069CQ35528811-53829F41-793E-4FC3-A5C8-BB76E13E36D2Q35743964-50A800D1-F162-4FE2-9AE0-426AC399428BQ35976459-3E5F83D2-120F-4EBA-800E-15A3BA11083CQ36359546-914F8C6D-3ECB-48EA-B7F4-C8278FE53580Q36378758-38E75F81-193F-49DC-A3F3-485FF7F757CAQ36618004-C505ACC6-A03C-4E41-8EBA-DB0B940F240FQ37351404-1361E331-B7C0-4789-95B5-66B0655EDAE3Q37672056-5EB3B489-956F-497C-B527-486CEA36FE59Q37810682-160FC10E-1815-42D7-823B-CB04C0E1D562Q38799171-F53BEA04-5D02-4720-A411-0A818112C915Q39675119-1CA4A22B-8388-4B13-B536-1FF605FE44ECQ39845435-4F394C5C-D957-47AD-9A07-E71CD1D6ACE7Q40789958-BE3720F5-EC07-4B82-B2B0-8E3CFC3B04ACQ40927325-F638945F-FA9A-4DA1-8A5A-5BC8148C3F98Q41741270-1A222340-DE13-4332-B731-3D4D292CD937Q42142955-C5D2F0EC-C4AC-408D-A79C-850C89CDCB9BQ42559551-4358BBA1-A496-4FDA-B259-49573DDE5537Q42794253-C198E888-5940-49A4-A2BA-08584448DFB7Q42855211-0B18BBCC-B149-4C00-B332-9E47E7A6EE7BQ42857563-19591ED7-5827-48FA-8F59-CC7A202C0500Q44938512-8DD3E057-A3F5-4B4C-942A-9878D7723D13Q49544329-75301067-6152-4265-8276-6E1308E9118CQ51579040-04F86407-C458-4FD0-98E0-65139375514DQ52327749-FD1829CA-9E78-4664-AB27-CCB5B833DF3F
P2860
Skeletal muscle metabolism in patients with malignant tumor.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年学术文章
@wuu
1976年学术文章
@zh-cn
1976年学术文章
@zh-hans
1976年学术文章
@zh-my
1976年学术文章
@zh-sg
1976年學術文章
@yue
1976年學術文章
@zh
1976年學術文章
@zh-hant
name
Skeletal muscle metabolism in patients with malignant tumor.
@en
type
label
Skeletal muscle metabolism in patients with malignant tumor.
@en
prefLabel
Skeletal muscle metabolism in patients with malignant tumor.
@en
P2093
P1476
Skeletal muscle metabolism in patients with malignant tumor.
@en
P2093
P304
P356
10.1016/0014-2964(76)90036-0
P577
1976-06-01T00:00:00Z